High numbers of PD-1 positive intra-tumor lymphocytes, CIK cell cytotoxicity and serum AFP were suggested to serve as prognostic factors to predict clinical outcomes related to CIK as an adjuvant therapy [56,57,58]. This evidence concerns the gene AFP and neoplasm.